Pioneering Artificial Intelligence company Novamente LLC has donated one percent of its common stock to the Methuselah Foundation. Currently in stealth mode, San Francisco-based Novamente is working on revolutionary Artificial Intelligence products. The Methuselah Foundation is a non-profit 501(c)(3) organization dedicated to accelerating the development of foreseeable, science-based therapies to combat aging.
Methuselah Foundation CEO David Gobel commented, “We are grateful to Novamente for its generous donation, the first we hope of many that will follow as part of the Methuselah Foundation’s newly launched “1% for Life” program, for far-sighted corporations that want to support the rapidly accelerating efforts to find solutions to the debilities caused by aging”.
Novamente President Bruce Klein observed, “Since both Novamente and the Methuselah Foundation are operating at the leading edge of scientific progress, we at Novamente appreciate the enormous benefits that progress in Artificial Intelligence and Life Extension will confer on humanity. We consider our donation a wise investment in a brighter future for us all”.
About the Methuselah Foundation
The Methuselah Foundation is a non-profit 501(c)(3) organization dedicated to accelerating the development of foreseeable, science-based therapies to combat aging. Its main activities are the funding of SENS research, and the Methuselah Mouse Prize, which is being offered to the scientific research teams that significantly extend the lifespan of middle-aged laboratory mice. Further details of the Methuselah Foundation can be found at: www.methuselahfoundation.org
Novamente is a software product and development firm aimed at bridging the gap between narrow and general purpose Artificial Intelligence. Ongoing research brings the company’s Novamente Cognition Engine closer each month to powerful Artificial General Intelligence. Further details on Novamente can be found at: www.novamente.net